CN111107846A - 烟碱乙酰胆碱受体的杂芳基变构调节剂 - Google Patents

烟碱乙酰胆碱受体的杂芳基变构调节剂 Download PDF

Info

Publication number
CN111107846A
CN111107846A CN201880060672.8A CN201880060672A CN111107846A CN 111107846 A CN111107846 A CN 111107846A CN 201880060672 A CN201880060672 A CN 201880060672A CN 111107846 A CN111107846 A CN 111107846A
Authority
CN
China
Prior art keywords
sulfonamide
pyridine
oxadiazol
dimethylcyclopropyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880060672.8A
Other languages
English (en)
Chinese (zh)
Inventor
I·M·贝尔
B·M·克罗利
P·J·曼利
W·D·什皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme BV
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of CN111107846A publication Critical patent/CN111107846A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880060672.8A 2017-09-19 2018-09-14 烟碱乙酰胆碱受体的杂芳基变构调节剂 Pending CN111107846A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560444P 2017-09-19 2017-09-19
US62/560,444 2017-09-19
PCT/US2018/050975 WO2019060210A1 (en) 2017-09-19 2018-09-14 HETEROARYLIC ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS

Publications (1)

Publication Number Publication Date
CN111107846A true CN111107846A (zh) 2020-05-05

Family

ID=65811090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880060672.8A Pending CN111107846A (zh) 2017-09-19 2018-09-14 烟碱乙酰胆碱受体的杂芳基变构调节剂

Country Status (6)

Country Link
US (1) US11198687B2 (enExample)
EP (1) EP3684357B1 (enExample)
JP (1) JP7221944B2 (enExample)
CN (1) CN111107846A (enExample)
CA (1) CA3073212A1 (enExample)
WO (1) WO2019060210A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11512092B2 (en) * 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) * 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
CN102448936A (zh) * 2009-04-25 2012-05-09 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
US20140031395A1 (en) * 2011-02-02 2014-01-30 Bionomics Limited Positive Allosteric Modulators of the Alpha 7 Nicotinic Acetylcholine Receptor and uses Thereof
CN104884432A (zh) * 2012-08-01 2015-09-02 默沙东公司 α7烟碱乙酰胆碱受体调节剂及其用途-I

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191799A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof
US9840481B2 (en) * 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585388A (en) * 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
CN102448936A (zh) * 2009-04-25 2012-05-09 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
US20140031395A1 (en) * 2011-02-02 2014-01-30 Bionomics Limited Positive Allosteric Modulators of the Alpha 7 Nicotinic Acetylcholine Receptor and uses Thereof
CN104884432A (zh) * 2012-08-01 2015-09-02 默沙东公司 α7烟碱乙酰胆碱受体调节剂及其用途-I

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王欢等: "α7烟碱型乙酰胆碱受体显像剂的设计合成及生物评价研究", 《第十三届全国放射性药物与标记化合物学术交流会》 *

Also Published As

Publication number Publication date
EP3684357A1 (en) 2020-07-29
EP3684357A4 (en) 2021-01-20
CA3073212A1 (en) 2019-03-28
WO2019060210A1 (en) 2019-03-28
JP7221944B2 (ja) 2023-02-14
US11198687B2 (en) 2021-12-14
US20200262826A1 (en) 2020-08-20
EP3684357B1 (en) 2022-12-28
JP2020535127A (ja) 2020-12-03

Similar Documents

Publication Publication Date Title
JP6526352B2 (ja) ニコチン性アセチルコリン受容体のアロステリック調節剤
JP7610985B2 (ja) 心臓サルコメア阻害剤
JP7221944B2 (ja) ニコチン性アセチルコリン受容体のヘテロアリールアロステリックモジュレーター
CN112119076B (zh) 烟碱乙酰胆碱受体的螺哌啶变构调节剂
KR20250005373A (ko) 통증 치료를 위한 헤테로아릴 화합물
TW200911254A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
JP2019536759A (ja) 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤
BR112019019740A2 (pt) compostos heterocíclicos substituídos como moduladores alostéricos de receptores de glutamato metabotrópicos de grupo ii
HK40070885A (en) Allosteric modulators of nicotinic acetylcholine receptors
BR112018069456B1 (pt) Composto útil como modulador de a7 nAChR ou um sal farmaceuticamente aceitável do mesmo, sua composição farmacêutica e seu uso
CN118515675A (zh) 一种α5-GABAA受体调节剂及其用途
CA3042707C (en) 3-substituted propionic acids as .alpha.v integrin inhibitors
EA035585B1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
HK1259808B (en) Allosteric modulators of nicotinic acetylcholine receptors
CA3038624A1 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
NZ785933A (en) Allosteric modulators of nicotinic acetylcholine receptors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220915

Address after: new jersey

Applicant after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Applicant before: MERCK SHARP & DOHME Corp.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200505